Semaglutide + NAD+: No Trial Evidence, FDA Warning
Semaglutide nad+: what compounded versions are, their FDA status, and the risks.
- Active ingredient
- semaglutide
- FDA status
- Compounded copies are not FDA approved
Wegovy, in brief
About 1 week is its half-life: by 7 d, half has gone; five half-lives (35 d) leave about 3%
In STEP 1, at 68 weeks, 14.9% of body weight was lost, against 2.4% on placebo.
Monthly prices in US dollars show list prices and self-pay offers. Each figure comes from the maker’s price page.
Sources: FDA label (DailyMed), healthsystemtracker.org, prnewswire.com 1 2.